RMTI - Rockwell Medical Inc Stock Price, Fair Value and News

1.47USD-0.06 (-3.92%)Market Closed

Market Summary

USD1.47-0.06

Market Closed

-3.92%

RMTI Stock Price

View Fullscreen

RMTI RSI Chart

RMTI Valuation

Market Cap

43.1M

Price/Earnings (Trailing)

-5.11

Price/Sales (Trailing)

0.52

EV/EBITDA

-1.47

Price/Free Cashflow

-4.58

RMTI Price/Sales (Trailing)

RMTI Profitability

EBT Margin

-33.14%

Return on Equity

-39.64%

Return on Assets

-16.18%

Free Cashflow Yield

-21.83%

RMTI Fundamentals

RMTI Revenue

Revenue (TTM)

83.6M

Rev. Growth (Yr)

14.39%

Rev. Growth (Qtr)

-7.06%

RMTI Earnings

Earnings (TTM)

-8.4M

Earnings Growth (Yr)

35.96%

Earnings Growth (Qtr)

19.23%

Breaking Down RMTI Revenue

Last 7 days

2.0%

Last 30 days

-11.1%

Last 90 days

11.8%

Trailing 12 Months

-31.2%

How does RMTI drawdown profile look like?

RMTI Financial Health

Current Ratio

1.73

Debt/Equity

0.39

Debt/Cashflow

-1.13

RMTI Investor Care

Shares Dilution (1Y)

133.69%

Diluted EPS (TTM)

-0.39

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	76.4M	75.8M	80.8M	83.6M
2022	62.6M	66.1M	68.8M	72.8M
2021	61.8M	61.1M	61.8M	61.9M
2020	61.6M	62.7M	62.5M	62.2M
2019	64.0M	63.9M	62.7M	61.3M
2018	57.7M	59.3M	61.4M	63.4M
2017	54.2M	54.0M	55.9M	57.3M
2016	55.1M	55.6M	54.0M	53.3M
2015	55.1M	55.0M	55.7M	55.4M
2014	53.0M	53.1M	53.7M	54.2M
2013	50.2M	51.0M	51.4M	52.4M
2012	47.7M	48.0M	48.7M	49.8M
2011	57.9M	54.2M	51.4M	49.0M
2010	0	56.3M	57.9M	59.6M
2009	0	0	0	54.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Rockwell Medical Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 17, 2024	timmins megan c.	sold (taxes)	-4,391	1.4	-3,137	evp, clo and secretary
Mar 17, 2024	strobeck mark	sold (taxes)	-8,541	1.4	-6,101	president and ceo
Mar 14, 2024	neri jesse	acquired	-	-	33,330	svp, finance
Mar 14, 2024	timmins megan c.	acquired	-	-	50,000	evp, clo and secretary
Mar 14, 2024	strobeck mark	acquired	-	-	100,000	president and ceo
Oct 16, 2023	lau joan	acquired	-	-	25,000	-
May 23, 2023	radie robert s	acquired	-	-	24,715	-
May 23, 2023	nissenson allen	acquired	-	-	24,715	-
May 23, 2023	smiley andrea heslin	acquired	-	-	24,715	-

Which funds bought or sold RMTI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	sold off	-100	-417,650	-	-%
Apr 09, 2024	Rise Advisors, LLC	unchanged	-	-49.00	357	-%
Mar 11, 2024	VANGUARD GROUP INC	added	185	1,247,930	2,031,700	-%
Feb 29, 2024	Scarborough Advisors, LLC	new	-	508	508	-%
Feb 15, 2024	JANE STREET GROUP, LLC	added	23.57	6,671	61,007	-%
Feb 15, 2024	BARCLAYS PLC	sold off	-100	-	-	-%
Feb 14, 2024	Stonebridge Capital Advisors LLC	sold off	-100	-227	-	-%
Feb 14, 2024	CITADEL ADVISORS LLC	new	-	45,059	45,059	-%
Feb 14, 2024	Royal Bank of Canada	new	-	-	-	-%
Feb 14, 2024	TWO SIGMA INVESTMENTS, LP	new	-	90,215	90,215	-%

Are Funds Buying or Selling RMTI?

Are funds buying RMTI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RMTI

No. of Funds

Unveiling Rockwell Medical Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.99%	3,380,534	SC 13G/A
Sep 06, 2023	richmond brothers, inc.	1%	55,510	SC 13D/A
Feb 23, 2023	richmond brothers, inc.	4.47%	519,980	SC 13G
Feb 14, 2023	davita inc.	9.9%	1,278,173	SC 13G/A
Feb 14, 2023	armistice capital, llc	9.99%	1,215,714	SC 13G
Jun 23, 2022	richmond brothers, inc.	6.3%	595,075	SC 13D/A
Apr 18, 2022	davita inc.	7.4%	7,500,000	SC 13G
Feb 24, 2022	blackrock inc.	1.0%	959,884	SC 13G/A
Feb 16, 2021	cvi investments, inc.	-	4,914,536	SC 13G/A
Feb 02, 2021	blackrock inc.	5.1%	4,790,950	SC 13G

Recent SEC filings of Rockwell Medical Inc

View All Filings

Date Filed	Form Type	Document
Apr 15, 2024	DEF 14A	DEF 14A
Apr 15, 2024	ARS	ARS
Mar 21, 2024	8-K	Current Report
Mar 21, 2024	8-K	Current Report
Mar 21, 2024	10-K	Annual Report
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 15, 2024	4	Insider Trading
Mar 15, 2024	4	Insider Trading
Mar 15, 2024	4	Insider Trading

Peers (Alternatives to Rockwell Medical Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	357.8B	85.2B	-3.67%	-8.64%	10.18	4.2	6.46%	95.94%
MRK	321.7B	60.1B	2.46%	9.45%	881.36	5.35	1.40%	-97.49%
PFE	148.3B	46.5B	-3.80%	-34.05%	-106.79	3.19	42.59%	-114.62%
AMGN	146.3B	28.2B	-0.95%	11.90%	21.78	5.19	7.09%	2.52%
GILD	83.6B	27.1B	-7.68%	-22.69%	14.75	3.08	-0.60%	23.36%
TEVA	14.6B	15.8B	-6.26%	55.93%	-25.3	0.92	6.17%	76.47%
MID-CAP
PRGO	4.2B	4.7B	-2.65%	-15.52%	-333.24	0.91	4.58%	90.97%
ALKS	4.1B	1.7B	-11.07%	-16.83%	11.58	2.48	49.61%	324.78%
BHC	3.1B	8.8B	-10.77%	12.83%	-5.28	0.36	7.79%	-163.11%
AMPH	2.0B	644.4M	-6.43%	-0.05%	14.34	3.06	29.14%	50.51%
SMALL-CAP
TLRY	1.4B	743.2M	-20.35%	-21.70%	-4.05	1.92	24.65%	80.36%
TXMD	22.3M	1.3M	-17.90%	-49.19%	-2.17	17.09	-98.14%	-109.18%
ACRX	16.3M	-	-14.29%	38.83%	-0.89	0.22	2882.68%	-138.52%
AGRX	2.7M	19.6M	-32.73%	-94.43%	-0.19	0.14	80.00%	43.08%
ACOR	645.9K	117.6M	-96.48%	-95.45%	0	0.01	-0.79%	-283.60%

Rockwell Medical Inc News

Latest updates

Rockwell Medical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-7.1%	22,093,000	23,771,000	18,080,000	19,668,000	19,313,000	18,691,000	18,682,000	16,124,000	15,332,500	15,988,000	15,137,000	15,473,000	15,164,000	15,280,000	15,896,000	15,857,000	15,491,000	15,407,000	14,846,000	15,559,000	16,854,259
Gross Profit	30.3%	2,870,000	2,202,000	1,033,000	2,599,000	2,340,500	777,000	1,745,000	-786,000	-2,230,500	-329,000	-262,000	401,000	385,000	346,000	881,000	1,113,000	1,112,230	-17,000	733,149	1,010,392	1,184,151
S&GA Expenses	-2.7%	541,000	556,000	530,000	498,000	351,000	762,000	526,000	455,000	873,000	1,541,000	1,468,000	1,851,000	2,132,500	1,669,000	1,997,000	2,073,000	1,901,313	1,827,000	2,218,997	3,102,378	395,712
R&D Expenses	-100.0%	-	494,000	167,000	278,000	-	469,000	926,000	1,567,000	-	1,221,000	2,416,000	1,809,000	-	1,745,000	1,616,000	1,822,000	-	1,475,000	2,958,276	497,276	1,608,823
EBITDA Margin	7.4%	-0.29	-0.31	-0.34	-0.33	-0.35	-0.36	-0.38	-0.40	-0.40	-0.40	-0.40	-0.40	-0.40	-0.41	-	-	-	-	-	-	-
Interest Expenses	169.6%	1,108,000	411,000	395,000	387,000	437,000	476,000	485,000	540,000	587,500	609,000	583,000	581,000	590,000	666,000	521,000	102,000	9,000	16,000	-	-	47,775
EBT Margin	3.3%	-0.33	-0.34	-0.37	-0.36	-0.38	-0.40	-0.42	-0.44	-0.45	-0.45	-0.45	-0.45	-0.45	-0.44	-	-	-	-	-	-	-
Net Income	19.2%	-1,512,000	-1,872,000	-3,305,000	-1,750,000	-2,361,000	-4,190,000	-4,967,000	-7,162,000	-8,941,000	-7,581,000	-8,400,000	-7,752,000	-8,663,000	-7,350,000	-6,893,000	-7,984,000	-7,302,000	-7,855,000	-10,292,000	-8,679,000	-9,375,913
Net Income Margin	12.2%	-0.10	-0.11	-0.15	-0.17	-0.26	-0.37	-0.43	-0.51	-0.53	-0.52	-0.53	-0.50	-0.50	-0.47	-	-	-	-	-	-	-
Free Cashflow	98.9%	-43,000	-3,753,000	-1,716,000	-3,900,000	-597,000	-1,102,000	-5,904,000	-9,811,000	-9,026,000	-7,075,000	-4,938,000	-12,495,000	-8,569,000	-4,918,000	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-0.8%	52.00	53.00	38.00	40.00	47.00	54.00	59.00	37.00	49.00	59.00	64.00	69.00	78.00	85.00	59.00	67.00	44.00	48.00	57.00	49.00	53.00
Current Assets	2.1%	29.00	28.00	28.00	30.00	35.00	42.00	47.00	25.00	35.00	46.00	52.00	59.00	69.00	78.00	52.00	59.00	37.00	41.00	48.00	40.00	47.00
Cash Equivalents	15.8%	9.00	8.00	9.00	11.00	10.00	13.00	31.00	10.00	13.00	23.00	32.00	36.00	49.00	57.00	27.00	37.00	12.00	14.00	21.00	21.00	23.00
Inventory	7.0%	6.00	5.00	6.00	6.00	6.00	5.00	5.00	6.00	4.00	4.00	5.00	4.00	4.00	4.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00
Net PPE	-5.4%	6.00	7.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00	3.00	2.00	3.00	3.00	2.00	2.00	2.00	3.00	3.00	3.00	3.00
Goodwill	0%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	-0.7%	31.00	31.00	29.00	28.00	33.00	38.00	39.00	42.00	46.00	48.00	45.00	43.00	44.00	43.00	42.00	45.00	24.00	24.00	27.00	29.00	25.00
Current Liabilities	-22.3%	17.00	21.00	17.00	15.00	18.00	19.00	19.00	20.00	21.00	22.00	34.00	11.00	13.00	13.00	11.00	13.00	12.00	12.00	15.00	16.00	13.00
Long Term Debt	149.0%	8.00	3.00	5.00	6.00	8.00	9.00	10.00	12.00	13.00	14.00	-	21.00	21.00	21.00	21.00	21.00	-	-	-	-	-
LT Debt, Current	-100.0%	-	6.00	5.00	3.00	2.00	5.00	5.00	7.00	7.00	7.00	21.00	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	149.0%	8.00	3.00	5.00	6.00	8.00	9.00	10.00	12.00	13.00	14.00	-	21.00	21.00	21.00	21.00	21.00	-	-	-	-	-
Shareholder's Equity	-1.1%	21.00	22.00	10.00	13.00	14.00	16.00	20.00	-	3.00	11.00	18.00	26.00	34.00	42.00	16.00	22.00	20.00	24.00	30.00	20.00	27.00
Retained Earnings	-0.4%	-397	-395	-393	-390	-388	-386	-382	-377	-370	-361	-353	-345	-337	-328	-321	-314	-306	-299	-291	-281	-272
Additional Paid-In Capital	0.3%	418	417	403	403	403	402	402	372	373	372	372	371	372	371	338	336	327	323	-	-	300
Shares Outstanding	2.2%	29.00	28.00	17.00	13.00	12.00	11.00	9.00	9.00	9.00	9.00	9.00	9.00	9.00	-	-	-	-	-	-	-	-
Float	-	-	-	91.00	-	-	-	11.00	-	-	-	29.00	-	-	-	112	-	-	-	153	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	98.9%	-43.00	-3,753	-1,716	-3,900	-112	-1,102	-5,904	-9,811	-9,026	-7,075	-4,938	-12,495	-8,569	-4,918	-9,616	-6,538	-5,300	-6,175	-10,354	-5,423	-5,784
Share Based Compensation	2.8%	218	212	309	193	220	177	97.00	-179	385	361	433	-236	751	250	-1,461	935	1,057	876	1,501	1,517	1,962
Cashflow From Investing	119.5%	2,008	-10,291	-64.00	5,302	3,218	-14,696	-51.00	9,133	540	-1,364	1,647	-512	637	1,875	-1,886	2,586	172	-1,141	-7,357	3,577	2,200
Cashflow From Financing	-105.8%	-742	12,845	-130	-631	-5,984	-2,002	26,823	-2,687	-1,624	-549	-6.00	-	-1.00	32,960	800	29,557	2,502	321	18,210	52.00	22,005

RMTI Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Net Sales	$ 83,612	$ 72,810
Cost of Sales	74,908	68,733
Gross Profit	8,704	4,077
Research and Product Development	1,107	3,119
Selling and Marketing	2,125	2,094
General and Administrative	12,142	15,644
Operating Loss	(6,670)	(16,780)
Other Expense:
Realized Gain on Investments	321	4
Interest Expense	(2,301)	(1,936)
Interest Income	211	33
Total Other Expense, net	(1,769)	(1,899)
Net Loss	$ (8,439)	$ (18,679)
Net Loss per Share, Basic (in dollars per share)	$ (0.37)	$ (1.31)
Net Loss per Share, Diluted (in dollars per share)	$ (0.37)	$ (1.31)
Weighted Average Shares Outstanding, Basic (in shares)	23,322,915	14,304,512
Weighted Average Shares Outstanding, Diluted (in shares)	23,322,915	14,304,512

RMTI Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
ASSETS
Cash and Cash Equivalents	$ 8,983	$ 10,102
Investments Available-for-Sale	1,952	11,390
Accounts Receivable, net of a reserve of $81 for 2023 and $33 for 2022	10,901	6,259
Inventory, net	5,871	5,814
Prepaid and Other Current Assets	1,063	1,745
Total Current Assets	28,770	35,310
Property and Equipment, net	6,402	2,194
Inventory, Non-Current	178	1,276
Right of Use Assets - Operating, net	2,713	3,943
Right of Use Assets - Financing, net	1,903	2,468
Intangible Assets, net	10,759	0
Goodwill	921	921
Other Non-Current Assets	527	523
Total Assets	52,173	46,635
LIABILITIES AND STOCKHOLDERS’ EQUITY
Insurance Financing Note Payable	244	503
Accounts Payable	4,516	4,053
Accrued Liabilities	7,149	7,702
Deferred Consideration, Current	2,500	0
Lease Liabilities - Operating, Current	1,381	1,483
Lease Liabilities - Financing, Current	558	522
Deferred License Revenue, Current	46	1,731
Term Loan, Current - Net of Issuance Costs and Premium Accretion	0	1,631
Customer Deposits	243	66
Total Current Liabilities	16,637	17,691
Lease Liabilities - Operating - Long-Term	1,433	2,581
Lease Liabilities - Financing - Long-Term	1,530	2,088
Term Loan - Long-Term, Net of Issuance Costs and Premium Accretion	8,293	7,555
Deferred License Revenue - Long-Term	475	2,600
Deferred Consideration - Long-Term	2,500	0
Long Term Liability - Other	14	14
Total Liabilities	30,882	32,529
Commitments and Contingencies (See Note 15)
Stockholders’ Equity:
Preferred Stock, $0.0001 par value, 2,000,000 shares authorized, 15,000 shares issued and outstanding at December 31, 2023 and 2022	0	0
Common Stock, $0.0001 par value, 170,000,000 shares authorized, 29,130,607 and 12,163,673 shares issued and outstanding at December 31, 2023 and 2022	3	1
Additional Paid-in Capital	418,487	402,701
Accumulated Deficit	(397,198)	(388,759)
Accumulated Other Comprehensive (Loss) Income	(1)	163
Total Stockholders’ Equity	21,291	14,106
Total Liabilities and Stockholders’ Equity	$ 52,173	$ 46,635

About Rockwell Medical Inc

Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in patients undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including cleaning agents, 6% bleach for disinfection, citric acid descale, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.

CEO	Dr. Mark Strobeck Ph.D.
WEBSITE	rockwellmed.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	253

Rockwell Medical Inc Frequently Asked Questions

What is the ticker symbol for Rockwell Medical Inc? What does RMTI stand for in stocks?

RMTI is the stock ticker symbol of Rockwell Medical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Rockwell Medical Inc (RMTI)?

As of Tue Apr 23 2024, market cap of Rockwell Medical Inc is 44.88 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RMTI stock?

You can check RMTI's fair value in chart for subscribers.

What is the fair value of RMTI stock?

You can check RMTI's fair value in chart for subscribers. The fair value of Rockwell Medical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Rockwell Medical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RMTI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Rockwell Medical Inc a good stock to buy?

The fair value guage provides a quick view whether RMTI is over valued or under valued. Whether Rockwell Medical Inc is cheap or expensive depends on the assumptions which impact Rockwell Medical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RMTI.

What is Rockwell Medical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, RMTI's PE ratio (Price to Earnings) is -5.32 and Price to Sales (PS) ratio is 0.54. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RMTI PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Rockwell Medical Inc's stock?

In the past 10 years, Rockwell Medical Inc has provided -0.172 (multiply by 100 for percentage) rate of return.